New hope for Drug-Resistant TB: experimental combo trial launches
Disease control
Recruiting now
This study tests a new drug called JDB0131, combined with other TB medications, in 60 people with rifampin-resistant tuberculosis. Participants will receive one of two doses of JDB0131 or a standard drug (delamanid) for 8 weeks. The goal is to see which combination clears the bac…
Phase: PHASE2 • Sponsor: WestVac Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC